Lund, Sweden, 12:00 pm CET, 31 March 2021 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today announced a change in the number of shares and votes. During March, the number of shares in BONESUPPORT HOLDING AB (publ) has increased with 55,000 and the number of votes has increased with 5,500 due to the direct share issue and repurchase of 55,000 series C shares as communicated on 15 March 2021.
As of 31 March 2021, the number of shares in BONESUPPORT HOLDING AB (publ) amounts to 65,064,222 shares, of which 63,774,222 are ordinary shares with one vote per share and 1,290,000 are series C shares with one-tenth of a vote per share. The number of votes in the company amounts to 63,903,222 votes.
For more information contact:
Emil Billbäck, CEO
+46 (0) 46 286 53 70
+46 (0) 708 76 87 87
The information in the press release is such that BONESUPPORT HOLDING AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 12:00 CET on 31 March 2021.
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits that its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 181 million in 2020. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.